Skip to main content
Cenra Inc. logo

Cenra Inc. — Investor Relations & Filings

Listed
Ticker · 3716 ISIN · TW0003716007 TW Manufacturing
Open in API
Filings indexed 410 across all filing types
Latest filing 2026-06-15 Board/Management Inform…
Country TW Taiwan
Listing TW 3716

About Cenra Inc.

https://www.cenra.com/

Cenra Inc. is a diversified healthcare enterprise with a history dating back to 1952. The company operates across a comprehensive value chain encompassing research and development, manufacturing, commercial marketing, and long-term care services. Its extensive portfolio includes active pharmaceutical ingredients (APIs), human pharmaceuticals, animal health products, and consumer health brands such as dietary supplements and personal care items. With a global reach spanning over 60 markets, the organization utilizes nine production bases and more than ten specialized technology platforms to deliver integrated health solutions. Cenra Inc. focuses on high-barrier oncology medications, complex generics, and 505(b)(2) drug developments. By integrating scientific innovation with rigorous operational management, the company provides accessible medical care and health services designed to meet evolving needs across all life stages.

Recent filings

Filing Released Lang Actions
代子公司「中化裕民健康事業股份有限公司」公告 董事會解除經理人競業禁止之限制
Board/Management Information Classification · 95% confidence The document is a disclosure from a listed company about a board resolution permitting a subsidiary's manager to engage in competitive business activities. It details the approval of this exception during a board meeting and mentions board voting outcomes. The content focuses on management and board decisions rather than financial results, audit, or general regulatory compliance filings. It specifically concerns an internal board matter related to managerial conduct and restrictions, which aligns best with Board/Management Information category. The document is brief and does not contain financial statements or detailed reports.
2026-06-15 Chinese
115年年報及股東會資料 — 2026_3716_20260526F05.pdf
AGM Information Classification · 90% confidence The document is the official minutes (“議事錄”) of the 115th Annual General Meeting of shareholders, detailing attendance, reports to the meeting, proposals, voting results, and appended materials (business report, financials, audit report, etc.). It is the record of an AGM, not simply an earnings release or proxy statement. This matches the definition for AGM Information (AGM-R).
2026-06-12 Chinese
115年年報及股東會資料 — 2025_3716_20260526FE4.pdf
Annual Report Classification · 98% confidence The document is titled “2025 Annual Report (Translation)” and contains comprehensive annual reporting content: company governance details, auditor information, detailed index of sections (business performance, financial status, risk analysis, corporate governance, funding status, etc.), full-year financial results with revenue, profit, EPS, and strategic outlook. It is not a short announcement or attestation but the full annual report itself. Therefore, it corresponds to the Annual Report category. FY 2025
2026-06-12 English
115年年報及股東會資料 — 2025_3716_20260526F04.pdf
Annual Report Classification · 99% confidence The document is titled “2025 Annual Report” (民國114年度年報), includes a detailed letter to shareholders, full financial performance data, business reviews, governance report, and comprehensive company information typical of a full-year report. It is not a short notice or transcript but the complete Annual Report itself. Therefore it matches the definition of a 10-K (Annual Report). FY 2025
2026-06-12 Chinese
代子公司「中國化學製藥股份有限公司」公告 內部稽核主管退休
Board/Management Information Classification · 85% confidence The document is a regulatory announcement disclosing the retirement of the internal audit chief (an “important operations executive” role) at a subsidiary. This falls under announcements of changes in senior management. Therefore, it is classified as Board/Management Information (MANG).
2026-06-12 Chinese
限制員工權利新股
Share Issue/Capital Change Classification · 96% confidence The document is a detailed issuance plan (“發行辦法”) for new restricted employee share rights, setting out the share quantity, vesting conditions, issuance methods, and capital change approvals. It is an announcement of a new share issue (free allotment to employees), matching the Share Issue/Capital Change category (SHA).
2026-06-11 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.